Ignite Creation Date:
2025-12-25 @ 2:21 AM
Ignite Modification Date:
2026-02-28 @ 7:10 PM
Study NCT ID:
NCT02323334
Status:
COMPLETED
Last Update Posted:
2021-04-19
First Post:
2014-12-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000544', 'term': 'Alzheimer Disease'}], 'ancestors': [{'id': 'D003704', 'term': 'Dementia'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D024801', 'term': 'Tauopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000719000', 'term': 'LY3202626'}, {'id': 'D017964', 'term': 'Itraconazole'}], 'ancestors': [{'id': 'D014230', 'term': 'Triazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D010879', 'term': 'Piperazines'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '800-545-5979', 'title': 'Chief Medical Officer', 'organization': 'Eli Lilly and Company'}, 'certainAgreement': {'restrictionType': 'GT60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Part A, B, and C Placebo', 'description': 'Single dose of placebo given PO in in capsule form, Part A and B. Multiple doses of placebo given PO in capsule form, Part C.', 'otherNumAtRisk': 36, 'otherNumAffected': 10, 'seriousNumAtRisk': 36, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Part A 0.1mg LY3202626', 'description': 'Single dose of 0.1mg LY3202626 given PO in in capsule form.', 'otherNumAtRisk': 8, 'otherNumAffected': 0, 'seriousNumAtRisk': 8, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Part A 0.4mg LY3202626', 'description': 'Single dose of 0.4mg LY3202626 given PO in in capsule form.', 'otherNumAtRisk': 8, 'otherNumAffected': 1, 'seriousNumAtRisk': 8, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Part A 0.4mg LY3202626 + 200mg Itraconazole', 'description': 'Single dose of 0.4mg LY3202626 +200mg Itraconazole given PO in in capsule form.', 'otherNumAtRisk': 12, 'otherNumAffected': 7, 'seriousNumAtRisk': 12, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Part C 1mg LY3202626 QD', 'description': 'Multiple daily dose of 1mg LY3202626 given PO in in capsule form.', 'otherNumAtRisk': 9, 'otherNumAffected': 4, 'seriousNumAtRisk': 9, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Part A and B 1.6mg LY3202626', 'description': 'Single dose of 1.6mg LY3202626 given PO in in capsule form..', 'otherNumAtRisk': 13, 'otherNumAffected': 4, 'seriousNumAtRisk': 13, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'Part A 5mg LY3202626', 'description': 'Single dose of 5mg LY3202626 given PO in in capsule form.', 'otherNumAtRisk': 8, 'otherNumAffected': 3, 'seriousNumAtRisk': 8, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Part C and Part D 6mg LY3202626 QD', 'description': 'Multiple daily dose of 6mg LY3202626 given PO in capsule form.', 'otherNumAtRisk': 11, 'otherNumAffected': 6, 'seriousNumAtRisk': 11, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'Part A and B 10mg LY3202626', 'description': 'Single dose of 10mg LY3202626 given PO in capsule form.', 'otherNumAtRisk': 19, 'otherNumAffected': 7, 'seriousNumAtRisk': 19, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'Part A 15mg LY3202626', 'description': 'Single dose of 15mg LY3202626 given PO in capsule form.', 'otherNumAtRisk': 11, 'otherNumAffected': 2, 'seriousNumAtRisk': 11, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'Part B and C 26mg LY3202626', 'description': 'Single dose of 26mg LY3202626 given PO in capsule form, Part B. Multiple daily dose of 26mg LY3202626 in in capsule form, Part C.', 'otherNumAtRisk': 14, 'otherNumAffected': 13, 'seriousNumAtRisk': 14, 'seriousNumAffected': 0}, {'id': 'EG011', 'title': 'Part A 45mg LY3202626', 'description': 'Single dose of 45mg LY3202626 given PO in in capsule form.', 'otherNumAtRisk': 8, 'otherNumAffected': 1, 'seriousNumAtRisk': 8, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Postural orthostatic tachycardia syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Dry eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Faeces discoloured', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Non-cardiac chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Post lumbar puncture syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 4, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 8, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 12, 'numAffected': 5}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 8, 'numAffected': 5}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Burning sensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Dysgeusia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Memory impairment', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Abnormal dreams', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Nightmare', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Rash erythematous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Hot flush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}, {'term': 'Orthostatic hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 36, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '19', 'groupId': 'OG008'}, {'value': '11', 'groupId': 'OG009'}, {'value': '14', 'groupId': 'OG010'}, {'value': '8', 'groupId': 'OG011'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A, B, and C Placebo (PBO)', 'description': 'Single dose placebo given PO in Part A and B. Multiple doses of PBO given PO in Part C.'}, {'id': 'OG001', 'title': 'Part A 0.1mg LY3202626', 'description': 'Single dose of 0.1mg LY3202626 given PO Period 1 Cohort 1.'}, {'id': 'OG002', 'title': 'Part A 0.4mg LY3202626', 'description': 'Single dose of 0.4mg LY3202626 given PO in Period 1 Cohort 2.'}, {'id': 'OG003', 'title': 'Part A 0.4mg LY3202626 + 200mg Itraconazole', 'description': 'Single dose of 0.4mg LY3202626 +200mg Itraconazole given PO in Period 4 Cohort 2.'}, {'id': 'OG004', 'title': 'Part C 1mg LY3202626 QD', 'description': 'Multiple daily dose of 1mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG005', 'title': 'Part A and B 1.6mg LY3202626', 'description': 'Single dose of 1.6mg LY3202626 given PO in Period 2 Cohort 1 in Part A and Period 1 Part B.'}, {'id': 'OG006', 'title': 'Part A 5mg LY3202626', 'description': 'Single dose of 5mg LY3202626 given PO in in Period 2 Cohort 2.'}, {'id': 'OG007', 'title': 'Part C and D 6mg LY3202626 QD', 'description': 'Multiple daily dose of 6mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG008', 'title': 'Part A, B and C 10mg LY3202626', 'description': 'Single dose of 10mg LY3202626 given PO in Part A and B. Multiple dose of 10mg LY3202626 given PO in Part C once daily for 14 days.'}, {'id': 'OG009', 'title': 'Part A 15mg LY3202626', 'description': 'Single dose of 15mg LY3202626 given PO in Period 3 Cohort 1.'}, {'id': 'OG010', 'title': 'Part B and C 26mg LY3202626', 'description': 'Single dose of 26mg LY3202626 given PO in Period 1 in Part B. Multiple daily dose of 26mg LY3202626 given PO once daily for 14 days in Part C.'}, {'id': 'OG011', 'title': 'Part A 45mg LY3202626', 'description': 'Single dose of 45mg LY3202626 given PO in in Period 3 Cohort 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline to Study Completion (up to 14 weeks)', 'description': "A summary of other nonserious Adverse Events (AE's), and all SAE's, regardless of causality, is located in the Reported Adverse Events section.", 'calculatePct': False, 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who received at least one dose of study drug.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '7', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '8', 'groupId': 'OG009'}, {'value': '9', 'groupId': 'OG010'}, {'value': '9', 'groupId': 'OG011'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A 0.1mg LY3202626', 'description': 'Single dose of 0.1mg LY3202626 given PO in Period 1 Cohort 1.'}, {'id': 'OG001', 'title': 'Part A 0.4mg LY3202626', 'description': 'Single dose of 0.4mg LY3202626 given PO in Period 1 Cohort 2.'}, {'id': 'OG002', 'title': 'Part A 1.6mg LY3202626', 'description': 'Single dose of 1.6mg LY3202626 given PO in Period 2 Cohort 1.'}, {'id': 'OG003', 'title': 'Part A 5mg LY3202626', 'description': 'Single dose of 5mg LY3202626 given PO in Period 2 Cohort 2.'}, {'id': 'OG004', 'title': 'Part A 15mg LY3202626', 'description': 'Single dose of 15mg LY3202626 given PO in Period 3 Cohort 1.'}, {'id': 'OG005', 'title': 'Part A 45mg LY3202626', 'description': 'Single dose of 45mg LY3202626 given PO in Period 3 Cohort 2.'}, {'id': 'OG006', 'title': 'Part B 1.6mg LY3202626', 'description': 'Single dose of 1.6mg LY3202626 given PO Period 1.'}, {'id': 'OG007', 'title': 'Part B 10mg LY3202626', 'description': 'Single dose of 10mg LY3202626 given PO in Period 1.'}, {'id': 'OG008', 'title': 'Part B 26mg LY3202626', 'description': 'Single dose of 26mg LY3202626 given PO in Period1.'}, {'id': 'OG009', 'title': 'Part C 1mg LY3202626 QD', 'description': 'Multiple doses of 1mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG010', 'title': 'Part C 6mg LY3202626 QD', 'description': 'Multiple doses of 6mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG011', 'title': 'Part C 26mg LY3202626 QD', 'description': 'Multiple doses of 26mg LY3202626 given PO once daily for 14 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.169', 'spread': '50', 'groupId': 'OG000'}, {'value': '0.486', 'spread': '81', 'groupId': 'OG001'}, {'value': '2.89', 'spread': '70', 'groupId': 'OG002'}, {'value': '7.91', 'spread': '56', 'groupId': 'OG003'}, {'value': '21.3', 'spread': '77', 'groupId': 'OG004'}, {'value': '92.5', 'spread': '47', 'groupId': 'OG005'}, {'value': '2.90', 'spread': '86', 'groupId': 'OG006'}, {'value': '3.75', 'spread': '176', 'groupId': 'OG007'}, {'value': '36.1', 'spread': '126', 'groupId': 'OG008'}, {'value': '2.57', 'spread': '2.5', 'groupId': 'OG009'}, {'value': '11.2', 'spread': '71', 'groupId': 'OG010'}, {'value': '72.8', 'spread': '61', 'groupId': 'OG011'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Part A and B Day 1:Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; Part C Day 1:Predose, 0.5,1, 2, 4, 6, 8, and 12 hours postdose; Part C Day 14:Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours postdose', 'description': 'Summary of PK parameters of LY3202626 in plasma following oral administration of single doses for Parts A and B and multiple doses for Part C.', 'unitOfMeasure': 'nanograms per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants in Part A, B, and C who received at least one dose of study drug and had evaluable PK data.'}, {'type': 'SECONDARY', 'title': 'PK: Area Under the Concentration Time Curve (AUC) of LY3202626', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '7', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '8', 'groupId': 'OG009'}, {'value': '9', 'groupId': 'OG010'}, {'value': '9', 'groupId': 'OG011'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A 0.1mg LY3202626', 'description': 'Single dose of 0.1mg LY3202626 given PO in Period 1 Cohort 1.'}, {'id': 'OG001', 'title': 'Part A 0.4mg LY3202626', 'description': 'Single dose of 0.4mg LY3202626 given PO in Period 1 Cohort 2.'}, {'id': 'OG002', 'title': 'Part A 1.6mg LY3202626', 'description': 'Single dose of 1.6mg LY3202626 given PO in Period 2 Cohort 1.'}, {'id': 'OG003', 'title': 'Part A 5mg LY3202626', 'description': 'Single dose of 5mg LY3202626 given PO in Period 2 Cohort 2.'}, {'id': 'OG004', 'title': 'Part A 15mg LY3202626', 'description': 'Single dose of 15mg LY3202626 given PO in Period 3 Cohort 1.'}, {'id': 'OG005', 'title': 'Part A 45mg LY3202626', 'description': 'Single dose of 45mg LY3202626 given PO in Period 3 Cohort 2.'}, {'id': 'OG006', 'title': 'Part B 1.6mg LY3202626', 'description': 'Single dose of 1.6mg LY3202626 given PO in Period 1.'}, {'id': 'OG007', 'title': 'Part B 10mg LY3202626', 'description': 'Single dose of 10mg LY3202626 given PO in Period 1.'}, {'id': 'OG008', 'title': 'Part B 26mg LY3202626', 'description': 'Single dose of 26mg LY3202626 given PO in Period 1.'}, {'id': 'OG009', 'title': 'Part C 1mg LY3202626 QD', 'description': 'Multiple doses of 1mg LY3202626 given PO once daily for 14 days..'}, {'id': 'OG010', 'title': 'Part C 6mg LY3202626 QD', 'description': 'Multiple doses of 6mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG011', 'title': 'Part C 26mg LY3202626 QD', 'description': 'Multiple doses of 26mg LY3202626 given PO once daily for 14 days.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'At doses less than 1.6 mg, the AUC(0-∞) could not be reliably quantified.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'At doses less than 1.6 mg, the AUC(0-∞) could not be reliably quantified.', 'groupId': 'OG001'}, {'value': '60.6', 'spread': '49', 'groupId': 'OG002'}, {'value': '197', 'spread': '38', 'groupId': 'OG003'}, {'value': '393', 'spread': '84', 'groupId': 'OG004'}, {'value': '1680', 'spread': '34', 'groupId': 'OG005'}, {'value': '49.9', 'spread': '41', 'groupId': 'OG006'}, {'value': '102', 'spread': '111', 'groupId': 'OG007'}, {'value': '575', 'spread': '62', 'groupId': 'OG008'}, {'value': '38.6', 'spread': '25', 'groupId': 'OG009'}, {'value': '151', 'spread': '54', 'groupId': 'OG010'}, {'value': '1020', 'spread': '50', 'groupId': 'OG011'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Part A and B Day 1: Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; Part C Day 1:Presdose, 0.5,1, 2, 4, 6, 8,12 hours postdose; Day 14: Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours postdose', 'description': 'Pharmacokinetic parameters for Part A and B were assessed on Day 1 using AUC 0-infinity (AUC0-inf). Pharmacokinetic parameters for Part C were assessed on Day 1 using AUC zero to time to last (AUC0-tlast), Day 14 using AUC steady state.', 'unitOfMeasure': 'nanogram x hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants in Parts A, B, and C who received at least one dose of study drug and had evaluable PK data.'}, {'type': 'SECONDARY', 'title': 'Pharmacodynamic(PD) Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}, {'value': '9', 'groupId': 'OG007'}, {'value': '9', 'groupId': 'OG008'}, {'value': '9', 'groupId': 'OG009'}, {'value': '9', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A Placebo', 'description': 'Single dose of placebo given PO in capsule form in Period 1-4.'}, {'id': 'OG001', 'title': 'Part A 0.1mg LY3202626', 'description': 'Single dose 0.1mg LY3202626 given PO in Period 1 Cohort 1.'}, {'id': 'OG002', 'title': 'Part A 0.4mg LY3202626', 'description': 'Single dose of 0.4mg LY3202626 given PO in Period 1 Cohort 2.'}, {'id': 'OG003', 'title': 'Part A 1.6 mg LY3202626', 'description': 'Single dose of 1.6mg LY3202626 given PO in Period 2 Cohort 1.'}, {'id': 'OG004', 'title': 'Part A 5mg LY3202626', 'description': 'Single dose of 5mg LY3202626 given PO in Period 2 Cohort 2.'}, {'id': 'OG005', 'title': 'Part A 15mg LY3202626', 'description': 'Single dose of 15mg LY3202626 given PO in Period 3 and Period 4 Cohort 1.'}, {'id': 'OG006', 'title': 'Part A 45mg LY3202626', 'description': 'Single dose of 45mg LY3202626 given PO in Period 3 Cohort 2.'}, {'id': 'OG007', 'title': 'Part C Placebo', 'description': 'Multiple doses of placebo given PO once daily for 14 days.'}, {'id': 'OG008', 'title': 'Part C 1mg LY3202626 QD', 'description': 'Multiple doses of 1mg LY3202626 in given PO once daily for 14 days.'}, {'id': 'OG009', 'title': 'Part C 6mg LY3202626 QD', 'description': 'Multiple doses of 6mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG010', 'title': 'Part C 26mg LY3202626 QD', 'description': 'Multiple doses of 26mg LY3202626 given PO once daily for 14 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '107', 'spread': '35.1', 'groupId': 'OG000'}, {'value': '58.1', 'spread': '150', 'groupId': 'OG001'}, {'value': '61.8', 'spread': '25.6', 'groupId': 'OG002'}, {'value': '33.4', 'spread': '62.0', 'groupId': 'OG003'}, {'value': '25.2', 'spread': '16.8', 'groupId': 'OG004'}, {'value': '17.0', 'spread': '33.6', 'groupId': 'OG005'}, {'value': '7.93', 'spread': '42.0', 'groupId': 'OG006'}, {'value': '84.6', 'spread': '26.5', 'groupId': 'OG007'}, {'value': '24.0', 'spread': '33.1', 'groupId': 'OG008'}, {'value': '5.80', 'spread': '51.9', 'groupId': 'OG009'}, {'value': '4.2', 'spread': '0', 'groupId': 'OG010'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Part A Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 postdose; Part C Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 120, 168, and 216 postdose', 'description': 'Plasma minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of plasma A-beta 1-40 following dose administration.', 'unitOfMeasure': 'Picogram per milliliter (pg/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants in Part A, Periods 1-3 and Part C, Period 3, who received at least one dose of study drug and had evaluable PD data analyzed per protocol. Participants in Part B and D were not assessed per protocol.'}, {'type': 'SECONDARY', 'title': 'PD Biomarker: Cerebral Spinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B Placebo', 'description': 'Single dose of placebo given PO in Period 1.'}, {'id': 'OG001', 'title': 'Part B 1.6 mg LY3202626', 'description': 'Single dose of 1.6mg LY3202626 given PO in Period 1.'}, {'id': 'OG002', 'title': 'Part B 6mg LY3202626', 'description': 'Single dose of 6mg LY3202626 given PO in Period 1.'}, {'id': 'OG003', 'title': 'Part B 26mg LY3202626', 'description': 'Single dose of 26mg LY3202626 given PO in Period 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '7980', 'spread': '53.8', 'groupId': 'OG000'}, {'value': '5700', 'spread': '22.3', 'groupId': 'OG001'}, {'value': '5770', 'spread': '41.8', 'groupId': 'OG002'}, {'value': '2980', 'spread': '46.4', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Part B: -4, -2, Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 24, 28, 32, and 36 hours postdose', 'description': 'CSF minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of CSF A-beta 1-40 following dose administration.', 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants in Part B who received at least one dose of study drug and had evaluable CSF PD data analyzed per protocol. Participants in Part A, C and D were not assessed per protocol.'}, {'type': 'SECONDARY', 'title': 'PK: CSF Concentration of LY3202626', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part C 1mg LY3202626', 'description': 'Multiple doses of 1mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG001', 'title': 'Part C 6 mg LY3202626', 'description': 'Multiple doses of 6mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG002', 'title': 'Part C 26mg LY3202626', 'description': 'Multiple doses of 26mg LY3202626 given PO once daily for 14 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.0648', 'spread': '46.2', 'groupId': 'OG000'}, {'value': '0.202', 'spread': '48.9', 'groupId': 'OG001'}, {'value': '1.26', 'spread': '44.8', 'groupId': 'OG002'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Part C: Day 15 at 24 hours +/- 4 hours (hr) postdose', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants in Part C who received at least one dose of study drug and had evaluable CSF PK data per protocol. Participants in Part A, B and D were not assessed per protocol.'}, {'type': 'SECONDARY', 'title': 'PD Biomarker: Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part C Placebo', 'description': 'Multiple doses of placebo given PO once daily for 14 days.'}, {'id': 'OG001', 'title': 'Part C 1mg LY3202626', 'description': 'Multiple doses of 1mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG002', 'title': 'Part C 6mg LY3202626', 'description': 'Multiple doses of 6mg LY3202626 given PO once daily for 14 days.'}, {'id': 'OG003', 'title': 'Part C 26mg LY3202626', 'description': 'Multiple doses of 26mg LY3202626 given PO once daily for 14 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '-21.3', 'spread': '16.8', 'groupId': 'OG000'}, {'value': '-50.1', 'spread': '8.56', 'groupId': 'OG001'}, {'value': '-75.7', 'spread': '7.38', 'groupId': 'OG002'}, {'value': '-93.7', 'spread': '2.39', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Parts C: Baseline, Day 15', 'description': 'CSF Aβ1-40 change from baseline at Day 15 endpoint, 24 hours postdose (+/- 4 hours) following multiple doses of LY3202626.', 'unitOfMeasure': 'percent change in concentration', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants in Part C who received at least one dose of study drug and had evaluable CSF PD data analyzed. Participants in Part A, B and D were not assessed per protocol.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Part A Cohort 1 Sequence 1: 0.1mg, 1.6mg, Placebo (PBO); 15mg', 'description': 'Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods. There was a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg PBO Period 4: 15mg LY3202626'}, {'id': 'FG001', 'title': 'Part A Cohort 1 Sequence 2: 1.6mg, PBO,15mg, 15mg', 'description': 'Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods. There was a washout period of approximately 14 days between doses.\n\nPeriod 1: 1.6mg LY3202626 Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626'}, {'id': 'FG002', 'title': 'Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, PBO', 'description': 'Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods. There was a washout period of approximately 14 days between doses.\n\nPeriod 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO'}, {'id': 'FG003', 'title': 'Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO; 0.4mg/200mg Itra', 'description': 'Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods. Period 4 includes 0.4mg LY3202626 and 200mg Itraconazole (Itra). There was a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg PBO Period 4: 0.4mg LY3202626/200mg Itraconazole'}, {'id': 'FG004', 'title': 'Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/200mg Itra', 'description': 'Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods. Period 4 includes 0.4mg LY3202626 and 200mg Itraconazole.There was a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.4mg LY3202626 Period 2: 5mg PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole'}, {'id': 'FG005', 'title': 'Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra', 'description': 'Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods. Period 4 includes 0.4mg LY3202626 and 200mg Itraconazole. There was a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.4mg PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole'}, {'id': 'FG006', 'title': 'Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted', 'description': 'Part A Cohort 3 involved healthy participants and was comprised of two treatment periods. Single dose of 10mg LY3202626 given PO in Period 1 and 2. There was a washout period of approximately 14 days between doses.\n\nPeriod 1: Fed Period 2: Fasted'}, {'id': 'FG007', 'title': 'Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed', 'description': 'Part A Cohort 3 involved healthy participants and was comprised of two treatment periods. Single dose 10mg LY3202626 given PO in Period 1 and 2.\n\nThere was a washout period of approximately 14 days between doses.\n\nPeriod 1: Fasted Period 2: Fed'}, {'id': 'FG008', 'title': 'Part B Cohort 4: 1.6mg', 'description': 'Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.'}, {'id': 'FG009', 'title': 'Part B Cohort 5: 10mg', 'description': 'Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.'}, {'id': 'FG010', 'title': 'Part B Cohort 6: 26mg', 'description': 'Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.'}, {'id': 'FG011', 'title': 'Part B Cohort 4, 5, 6: PBO Comparator', 'description': 'Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.'}, {'id': 'FG012', 'title': 'Part C Cohort 7: 1mg', 'description': 'Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.'}, {'id': 'FG013', 'title': 'Part C Cohort 8: 6mg', 'description': 'Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.'}, {'id': 'FG014', 'title': 'Part C Cohort 9: 26mg', 'description': 'Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.'}, {'id': 'FG015', 'title': 'Part C Cohort 7, 8 ,9: PBO Comparator', 'description': 'Part C Cohort 7, 8, 9 involved healthy participants and was comprised of one period. PBO given PO once daily for 14 days.'}, {'id': 'FG016', 'title': 'Part D Cohort 10: 6mg', 'description': "Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B."}], 'periods': [{'title': 'Period 1', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '6'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'groupId': 'FG008', 'numSubjects': '5'}, {'groupId': 'FG009', 'numSubjects': '7'}, {'groupId': 'FG010', 'numSubjects': '5'}, {'groupId': 'FG011', 'numSubjects': '3'}, {'groupId': 'FG012', 'numSubjects': '9'}, {'groupId': 'FG013', 'numSubjects': '9'}, {'groupId': 'FG014', 'numSubjects': '9'}, {'groupId': 'FG015', 'numSubjects': '9'}, {'groupId': 'FG016', 'numSubjects': '2'}]}, {'type': 'Received at Least One Dose of Study Drug', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '6'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'groupId': 'FG008', 'numSubjects': '5'}, {'groupId': 'FG009', 'numSubjects': '7'}, {'groupId': 'FG010', 'numSubjects': '5'}, {'groupId': 'FG011', 'numSubjects': '3'}, {'groupId': 'FG012', 'numSubjects': '9'}, {'groupId': 'FG013', 'numSubjects': '9'}, {'groupId': 'FG014', 'numSubjects': '9'}, {'groupId': 'FG015', 'numSubjects': '9'}, {'groupId': 'FG016', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '6'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'groupId': 'FG008', 'numSubjects': '5'}, {'groupId': 'FG009', 'numSubjects': '7'}, {'groupId': 'FG010', 'numSubjects': '5'}, {'groupId': 'FG011', 'numSubjects': '3'}, {'groupId': 'FG012', 'numSubjects': '9'}, {'groupId': 'FG013', 'numSubjects': '9'}, {'groupId': 'FG014', 'numSubjects': '9'}, {'groupId': 'FG015', 'numSubjects': '9'}, {'groupId': 'FG016', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}]}, {'title': 'Period 2', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '6'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'comment': 'Part B was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG008', 'numSubjects': '0'}, {'comment': 'Part B was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG009', 'numSubjects': '0'}, {'comment': 'Part B was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG010', 'numSubjects': '0'}, {'comment': 'Part B was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG011', 'numSubjects': '0'}, {'comment': 'Part C was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG012', 'numSubjects': '0'}, {'comment': 'Part C was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG013', 'numSubjects': '0'}, {'comment': 'Part C was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG014', 'numSubjects': '0'}, {'comment': 'Part C was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG015', 'numSubjects': '0'}, {'comment': 'Part D was a single period conducted in parallel to Part A and received last dose in Period 1.', 'groupId': 'FG016', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '6'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}]}, {'title': 'Period 3', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'comment': 'Part A Cohort 3 Food Effect participated in Period 1 and Period 2 only.', 'groupId': 'FG006', 'numSubjects': '0'}, {'comment': 'Part A Cohort 3 Food Effect participated in Period 1 and Period 2 only.', 'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}]}, {'title': 'Period 4', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '12', 'groupId': 'BG006'}, {'value': '12', 'groupId': 'BG007'}, {'value': '12', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '94', 'groupId': 'BG010'}]}], 'groups': [{'id': 'BG000', 'title': 'Part A Cohort 1', 'description': 'Escalating single dose given orally (PO)per randomly assigned treatment sequence of 0.1mg, 1.6mg, 15mg LY3202626 or placebo.'}, {'id': 'BG001', 'title': 'Part A Cohort 2', 'description': 'Escalating single dose given PO per randomly assigned treatment sequence of 0.4mg, 5mg, or 45mg LY3202626, placebo.\n\nSome participants may also receive multiple doses of 200 mg of Itraconazole PO in 1 period with 0.4mg of LY3202626.'}, {'id': 'BG002', 'title': 'Part A Food Effect Cohort 3', 'description': 'Single dose of 10mg LY3202626 given PO in Period 1 and Period 2 only.'}, {'id': 'BG003', 'title': 'Part B Cohort 4', 'description': 'Single oral dose of 1.6mg LY3202626 or placebo given PO in Period 1. Dose determined by Part A.'}, {'id': 'BG004', 'title': 'Part B Cohort 5', 'description': 'Single oral dose of 10mg LY3202626 or placebo given PO in in Period 1. Dose determined by Part A.'}, {'id': 'BG005', 'title': 'Part B Cohort 6', 'description': 'Single oral dose of 26mg LY3202626 or placebo given PO in Period 1. Dose determined by Part A.'}, {'id': 'BG006', 'title': 'Part C Cohort 7', 'description': 'Multiple oral doses of 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.'}, {'id': 'BG007', 'title': 'Part C Cohort 8', 'description': 'Multiple oral doses of 6mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.'}, {'id': 'BG008', 'title': 'Part C Cohort 9', 'description': 'Multiple oral doses of 26mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.'}, {'id': 'BG009', 'title': 'Part D Cohort 10', 'description': 'Multiple oral doses of 6mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.'}, {'id': 'BG010', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '33.0', 'spread': '8.1', 'groupId': 'BG000'}, {'value': '36.9', 'spread': '8.4', 'groupId': 'BG001'}, {'value': '39.0', 'spread': '13.6', 'groupId': 'BG002'}, {'value': '36.5', 'spread': '12.4', 'groupId': 'BG003'}, {'value': '43.0', 'spread': '11.3', 'groupId': 'BG004'}, {'value': '35.2', 'spread': '7.2', 'groupId': 'BG005'}, {'value': '37.5', 'spread': '10.5', 'groupId': 'BG006'}, {'value': '40.4', 'spread': '8.1', 'groupId': 'BG007'}, {'value': '40.5', 'spread': '10.5', 'groupId': 'BG008'}, {'value': '68.0', 'spread': '2.8', 'groupId': 'BG009'}, {'value': '38.70', 'spread': '10.93', 'groupId': 'BG010'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '10', 'groupId': 'BG010'}]}, {'title': 'Male', 'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '12', 'groupId': 'BG006'}, {'value': '11', 'groupId': 'BG007'}, {'value': '11', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '84', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '3', 'groupId': 'BG007'}, {'value': '3', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '18', 'groupId': 'BG010'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '10', 'groupId': 'BG006'}, {'value': '9', 'groupId': 'BG007'}, {'value': '9', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '76', 'groupId': 'BG010'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}]}, {'title': 'Asian', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '4', 'groupId': 'BG007'}, {'value': '4', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '30', 'groupId': 'BG010'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}, {'value': '3', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '18', 'groupId': 'BG010'}]}, {'title': 'White', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '5', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '5', 'groupId': 'BG007'}, {'value': '7', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '44', 'groupId': 'BG010'}]}, {'title': 'More than one race', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2', 'groupId': 'BG010'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '12', 'groupId': 'BG006'}, {'value': '12', 'groupId': 'BG007'}, {'value': '12', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '94', 'groupId': 'BG010'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}], 'populationDescription': 'Received at least one dose of study drug.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 94}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-03', 'completionDateStruct': {'date': '2016-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-03-22', 'studyFirstSubmitDate': '2014-12-08', 'resultsFirstSubmitDate': '2021-03-22', 'studyFirstSubmitQcDate': '2014-12-17', 'lastUpdatePostDateStruct': {'date': '2021-04-19', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-03-22', 'studyFirstPostDateStruct': {'date': '2014-12-23', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2021-04-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'timeFrame': 'Baseline to Study Completion (up to 14 weeks)', 'description': "A summary of other nonserious Adverse Events (AE's), and all SAE's, regardless of causality, is located in the Reported Adverse Events section."}], 'secondaryOutcomes': [{'measure': 'Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626', 'timeFrame': 'Part A and B Day 1:Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; Part C Day 1:Predose, 0.5,1, 2, 4, 6, 8, and 12 hours postdose; Part C Day 14:Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours postdose', 'description': 'Summary of PK parameters of LY3202626 in plasma following oral administration of single doses for Parts A and B and multiple doses for Part C.'}, {'measure': 'PK: Area Under the Concentration Time Curve (AUC) of LY3202626', 'timeFrame': 'Part A and B Day 1: Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; Part C Day 1:Presdose, 0.5,1, 2, 4, 6, 8,12 hours postdose; Day 14: Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours postdose', 'description': 'Pharmacokinetic parameters for Part A and B were assessed on Day 1 using AUC 0-infinity (AUC0-inf). Pharmacokinetic parameters for Part C were assessed on Day 1 using AUC zero to time to last (AUC0-tlast), Day 14 using AUC steady state.'}, {'measure': 'Pharmacodynamic(PD) Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration', 'timeFrame': 'Part A Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 postdose; Part C Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 120, 168, and 216 postdose', 'description': 'Plasma minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of plasma A-beta 1-40 following dose administration.'}, {'measure': 'PD Biomarker: Cerebral Spinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration', 'timeFrame': 'Part B: -4, -2, Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 24, 28, 32, and 36 hours postdose', 'description': 'CSF minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of CSF A-beta 1-40 following dose administration.'}, {'measure': 'PK: CSF Concentration of LY3202626', 'timeFrame': 'Part C: Day 15 at 24 hours +/- 4 hours (hr) postdose'}, {'measure': 'PD Biomarker: Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration', 'timeFrame': 'Parts C: Baseline, Day 15', 'description': 'CSF Aβ1-40 change from baseline at Day 15 endpoint, 24 hours postdose (+/- 4 hours) following multiple doses of LY3202626.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Healthy Volunteers', 'Alzheimer Disease']}, 'descriptionModule': {'briefSummary': "This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single increasing doses of LY3202626 will be given in capsule form. Part A will also include itraconazole given orally as a solution. Part A will last approximately 8-12 weeks. Part B will last approximately 5-6 weeks. In Parts C and D, participants will be dosed multiple days with the study drug. Part C will last approximately 11-14 weeks. Part D will last approximately 11-14 weeks and participants must have Alzheimer's Disease. Participants may only enroll in one part."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '20 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* For Parts A, B, and C, are overtly healthy males or females (nonchildbearing potential), as determined by medical history and physical examination\n* Have a body mass index (BMI) of 18 to 32 kilograms per square meter (kg/m\\^2)\n* For Part D, present with Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD) or mild to moderate AD\n* Have venous access sufficient to allow for blood sampling\n* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures and research unit policies\n\nExclusion Criteria:\n\n* Taking over-the-counter or prescription medication with the exception of vitamins or minerals\n* Smoke more than 10 cigarettes per day\n* Are unwilling or unable to refrain from eating any food or drinking any beverage containing grapefruit or grapefruit juice for at least 2 weeks prior to first dose until completion of the study"}, 'identificationModule': {'nctId': 'NCT02323334', 'briefTitle': "A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease", 'organization': {'class': 'INDUSTRY', 'fullName': 'Eli Lilly and Company'}, 'officialTitle': 'Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626', 'orgStudyIdInfo': {'id': '15562'}, 'secondaryIdInfos': [{'id': 'I7X-EW-LLCA', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg', 'description': 'Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg placebo (PBO) Period 4: 15mg LY3202626.', 'interventionNames': ['Drug: LY3202626', 'Drug: Placebo (Part A, B, C)']}, {'type': 'EXPERIMENTAL', 'label': 'Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg', 'description': 'Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.1mg Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626.', 'interventionNames': ['Drug: LY3202626', 'Drug: Placebo (Part A, B, C)']}, {'type': 'EXPERIMENTAL', 'label': 'Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo', 'description': 'Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.\n\nPeriod 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO.', 'interventionNames': ['Drug: LY3202626', 'Drug: Placebo (Part A, B, C)']}, {'type': 'EXPERIMENTAL', 'label': 'Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole', 'description': 'Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg, PBO Period 4: 0.4mg LY3202626/200mg Itraconazole.', 'interventionNames': ['Drug: LY3202626', 'Drug: Placebo (Part A, B, C)']}, {'type': 'EXPERIMENTAL', 'label': 'Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra', 'description': 'Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.4mg LY3202626 Period 2: 5mg, PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole.', 'interventionNames': ['Drug: LY3202626', 'Drug: Placebo (Part A, B, C)', 'Drug: Itraconazole']}, {'type': 'EXPERIMENTAL', 'label': 'Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra', 'description': 'Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.\n\nPeriod 1: 0.4mg, PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole.', 'interventionNames': ['Drug: LY3202626', 'Drug: Placebo (Part A, B, C)', 'Drug: Itraconazole']}, {'type': 'EXPERIMENTAL', 'label': 'Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted', 'description': 'Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose of 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fed 2: Fasted.', 'interventionNames': ['Drug: LY3202626']}, {'type': 'EXPERIMENTAL', 'label': 'Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed', 'description': 'Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fasted 2: Fed.', 'interventionNames': ['Drug: LY3202626']}, {'type': 'EXPERIMENTAL', 'label': 'Part B Cohort 4: 1.6mg', 'description': 'Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.', 'interventionNames': ['Drug: LY3202626']}, {'type': 'EXPERIMENTAL', 'label': 'Part B Cohort 5: 10mg', 'description': 'Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.', 'interventionNames': ['Drug: LY3202626']}, {'type': 'EXPERIMENTAL', 'label': 'Part B Cohort 6: 26mg', 'description': 'Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.', 'interventionNames': ['Drug: LY3202626']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part B Cohort 4, 5, 6: Placebo Comparator', 'description': 'Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.', 'interventionNames': ['Drug: Placebo (Part A, B, C)']}, {'type': 'EXPERIMENTAL', 'label': 'Part C Cohort 7: 1mg', 'description': 'Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.', 'interventionNames': ['Drug: LY3202626']}, {'type': 'EXPERIMENTAL', 'label': 'Part C Cohort 8: 6mg', 'description': 'Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.', 'interventionNames': ['Drug: LY3202626']}, {'type': 'EXPERIMENTAL', 'label': 'Part C Cohort 9: 26mg', 'description': 'Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.', 'interventionNames': ['Drug: LY3202626']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part C Cohort 7, 8 ,9: Placebo Comparator', 'description': 'Part C Cohort 7,8,9 involved healthy participants and was comprised of one period. Placebo given PO once daily for 14 days.', 'interventionNames': ['Drug: Placebo (Part A, B, C)']}, {'type': 'EXPERIMENTAL', 'label': 'Part D Cohort 10: 6mg', 'description': "Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.", 'interventionNames': ['Drug: LY3202626']}], 'interventions': [{'name': 'LY3202626', 'type': 'DRUG', 'description': 'administered orally', 'armGroupLabels': ['Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg', 'Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo', 'Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg', 'Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole', 'Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra', 'Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra', 'Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted', 'Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed', 'Part B Cohort 4: 1.6mg', 'Part B Cohort 5: 10mg', 'Part B Cohort 6: 26mg', 'Part C Cohort 7: 1mg', 'Part C Cohort 8: 6mg', 'Part C Cohort 9: 26mg', 'Part D Cohort 10: 6mg']}, {'name': 'Placebo (Part A, B, C)', 'type': 'DRUG', 'description': 'administered orally', 'armGroupLabels': ['Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg', 'Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo', 'Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg', 'Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole', 'Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra', 'Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra', 'Part B Cohort 4, 5, 6: Placebo Comparator', 'Part C Cohort 7, 8 ,9: Placebo Comparator']}, {'name': 'Itraconazole', 'type': 'DRUG', 'description': 'administered orally', 'armGroupLabels': ['Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra', 'Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra']}]}, 'contactsLocationsModule': {'locations': [{'zip': '91206', 'city': 'Glendale', 'state': 'California', 'country': 'United States', 'facility': 'California Clinical Trials Medical Group', 'geoPoint': {'lat': 34.14251, 'lon': -118.25508}}], 'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Eli Lilly and Company'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}